TrialPOC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
Trial details
- Registry ID
- NCT05953688
- Phase
- Phase 2
Drug research
ESK-001
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUNCT05953688 | ALMS | Phase 2 | Terminated | 2024-08-13Actual |
| A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisNCT05600036 | ALMS | Phase 2 | Completed | 2023-06-29Actual |
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
Trial details
- Registry ID
- NCT05600036
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |